Ignite Creation Date:
2025-12-25 @ 3:29 AM
Ignite Modification Date:
2026-03-28 @ 1:50 PM
Study NCT ID:
NCT06992505
Status:
COMPLETED
Last Update Posted:
2025-12-02
First Post:
2025-05-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Assessment of Macrophage Activation syndromE in STill's Disease in Italy
Sponsor:
Swedish Orphan Biovitrum
Organization:
Study Overview
Official Title:
Assessment of Macrophage Activation syndromE in STill's Disease: Retrospective Chart Analysis of Patient hIstory, Symptom Resolution and TreAtment Characteristics in Italy (AMETISTA)
Status:
COMPLETED
Status Verified Date:
2025-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AMETISTA
Brief Summary:
Assessment of macrophage activation syndrome in Still's disease:
retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy
retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy
Detailed Description:
This is an observational, retrospective cohort study on the treatment utilization and outcomes of Macrophage Activation Syndrome (MAS) refractory to glucocorticoids (GC) in patients with Still's disease. The study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments. The study will be conducted in Italy.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: